Key Takeaways
- Insmed shares jumped 18% after Bloomberg reported that Sanofi is weighing an acquisition of the company.
- Sanofi is looking for growth to replace Dupixent, and Insmed’s Brinsupri is tracking to $1.35 billion to $1.4 billion in its first full year on the market.
- Neither company has confirmed talks, and any deal could still be weeks away.
- Even after the jump, Insmed trades well below its five-year average multiple of forward sales, which should cushion the stock if talks go nowhere.
Insmed (INSM) shares jumped 18% today after Bloomberg reported that Sanofi (SNY) is weighing a takeover of the company.
Sanofi is reportedly speaking with advisers, and any deal could still be weeks away. Both companies declined to comment. Sanofi shares are down 2%.
Sanofi needs life after Dupixent
Sanofi isn’t hurting today. Its third-quarter sales rose 14.3% at constant currency, and Dupixent sales jumped 34.8% to €5.7 billion. But CEO Belén Garijo said in Sanofi’s third-quarter release that the company’s priority is protecting earnings through Dupixent’s loss of exclusivity, and that “Business development and M&A will be critical to complement this transformation.”
Insmed would be a big bite. Before today, it was worth about $26 billion, nearly a quarter of Sanofi’s roughly $111 billion market value.
TIKR tracks 24 analysts on Insmed. How many say “Buy”?
See the full breakdown of Buy, Hold, and Sell ratings on Insmed, along with Wall Street’s revenue and earnings estimates, all in one place. More than 500,000 investors use TIKR to research stocks like this one. See Insmed’s Analyst Ratings
Brinsupri is just getting started
Insmed’s third-quarter revenue came in at $524.4 million, and Brinsupri brought in $400.1 million of it, up 29% from the second quarter. Insmed then raised its 2026 Brinsupri guidance to $1.35 billion to $1.4 billion, in the drug’s first full year on the market. And at the Jefferies Global Healthcare Conference on Monday, CEO Will Lewis said “we are basically 10% penetrated” in the US bronchiectasis market.
Analysts expect Insmed’s revenue to more than double from this year’s estimate by 2028:

A buyer would also get a company that has almost stopped burning cash. Free cash flow improved from negative $222 million in the third quarter of 2025 to negative $42 million in the third quarter of 2026, and management expects Insmed to become cash-flow positive:

A cushion if Sanofi walks away
This is still just a report, though. If talks go nowhere, I’d expect Insmed to give back much of today’s jump, which is worth about $5 billion of market value.
But the stock wasn’t expensive going in. Before today’s jump, Insmed traded at 9.6x forward sales, about half its five-year average of 19x:

At today’s price, it’s about 11x, which is still well below that average.
The way I see it, Sanofi’s interest mostly confirms what Insmed’s numbers already show, and I’d be comfortable owning the stock with or without a deal. The next test is Insmed’s fourth-quarter report early next year. If Brinsupri sales land within the $1.35 billion to $1.4 billion guide, the case for Insmed on its own holds up, whatever Sanofi decides.
So what is Insmed stock actually worth?
TIKR lets you forecast the future price of any stock in less than a minute. Just enter a few assumptions into TIKR’s valuation model and see what Insmed could be worth. Start from Wall Street consensus estimates, or adjust the inputs to reflect your own view of the business. It’s free to use.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any of the stocks mentioned. Thank you for reading, and happy investing!